Dr. Einat Zisman is the CEO of FutuRx Ltd., the Israeli Biotechnology accelerator that was established in January 2014 by OrbiMed Israel Partners, Johnson & Johnson Innovation, JJDC and Takeda Pharmaceutical Company, through its venture group Takeda Ventures Inc. after winning the tender of the Office of the Chief Scientist (OCS) in Israel.
Prior to joining FutuRx, Dr. Zisman served as the CEO of Hadasit Medical Research Services & Development Ltd., the Technology Transfer Organization (TTO) and commercial arm of Hadassah Medical Organization in Jerusalem, Israel. Before joining Hadasit, Dr. Zisman served as the Chief Business Officer of Yeda, the technology transfer arm of the Weizmann Institute of Science.
Dr. Zisman holds an MBA from the Marshall Business School, University of Southern California, USA, a PhD from the Weizmann Institute of Science and a B.Pharm degree from the Hebrew University of Jerusalem. Dr. Zisman’s expertise is in building value via licensing, partnering, financing and marketing of early stage technologies.